title: The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.
abstract: UDP-glucuronosyltransferases (UGTs) play an important role in the phase II metabolism of exogenous and endogenous compounds. As colorectal cancer (CRC) etiology is thought to involve the biotransformation of dietary factors, UGT polymorphisms may affect CRC risk by altering levels of exposure. Genotyping of over 1800 Caucasian subjects was completed to identify the role of genetic variation in nine UGT1A and five UGT2B genes on CRC risk. Unconditional logistic regression and haplotype analyses were conducted to identify associations with CRC risk and potential gene-environment interactions. UGT1A haplotype analysis found that the T-G haplotype in UGT1A10 exon 1 (block 2: rs17864678, rs10929251) decreased cancer risk for the colon [proximal (OR = 0.28, 95% CI = 0.11–0.69) and for the distal colon (OR = 0.32, 95% CI = 0.12–0.91)], and that the C-T-G haplotype in the 3′ region flanking the UGT1A shared exons (block 11: rs7578153, rs10203853, rs6728940) increased CRC risk in males (OR = 2.56, 95% CI = 1.10–5.95). A haplotype in UGT2B15 containing a functional variant (rs4148269, K523T) and an intronic SNP (rs6837575) was found to affect rectal cancer risk overall (OR = 2.57, 95% CI = 1.21–5.04) and in females (OR = 3.08, 95% CI = 1.08–8.74). An interaction was found between high NSAID use and the A-G-T haplotype (block 10: rs6717546, rs1500482, rs7586006) in the UGT1A shared exons that decreased CRC risk. This suggests that UGT genetic variation alters CRC risk differently by anatomical sub-site and gender and that polymorphisms in the UGT1A shared exons may have a regulatory effect on gene expression that allows for the protective effect of NSAIDs on CRC risk.
authors.forename: Andrea Y
authors.initials: AY
authors.lastname: Angstadt
authors.forename: Terryl J
authors.initials: TJ
authors.lastname: Hartman
authors.forename: Samuel M
authors.initials: SM
authors.lastname: Lesko
authors.forename: Joshua E
authors.initials: JE
authors.lastname: Muscat
authors.forename: Junjia
authors.initials: J
authors.lastname: Zhu
authors.forename: Carla J
authors.initials: CJ
authors.lastname: Gallagher
authors.forename: Philip
authors.initials: P
authors.lastname: Lazarus
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016022:Case-Control Studies; D002889:Chromosomes, Human, Pair 2; D002894:Chromosomes, Human, Pair 4; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000378:metabolism; D005260:Female; D059647:Gene-Environment Interaction; D056726:Genetic Association Studies; D014453:Glucuronosyltransferase / Q000235:genetics*; D006239:Haplotypes; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D012306:Risk; D012307:Risk Factors; D000099148:UGT1A1 Enzyme
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D014453:Glucuronosyltransferase; D000099148:UGT1A1 Enzyme; C472000:UDP-glucuronosyltransferase 2B15, human